COMMUNIQUÉS West-GlobeNewswire

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
25/04/2024
Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million [...]
Microbix Collaborator Introduces New Lab Accreditation Program
25/04/2024
Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted Infection MISSISSAUGA, Ontario, April 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life [...]
TELA Bio to Announce First Quarter 2024 Financial Results
25/04/2024
MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
25/04/2024
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 [...]
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
25/04/2024
WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein [...]
Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients
25/04/2024
DURHAM, N.C. and DENVER, April 25, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and [...]
Nexstim Plc: Managers’ Transactions, Hildén
25/04/2024
Company Announcement, Helsinki, 25 April 2024 at 1:15 PM (EEST) Nexstim Plc: Managers’ Transactions, Hildén Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to [...]
Nexstim Plc: Managers’ Transactions, Forss
25/04/2024
Company Announcement, Helsinki, 25 April 2024 at 1:10 PM (EEST) Nexstim Plc: Managers’ Transactions, Forss Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to [...]
Nexstim Plc: Managers’ Transactions, Weckroth
25/04/2024
Company Announcement, Helsinki, 25 April 2024 at 1:05 PM (EEST) Nexstim Plc: Managers’ Transactions, Weckroth Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject [...]
MEDIROM Healthcare Technologies Inc. Announces March 2024 Key Performance Indicators (KPIs)
25/04/2024
Total Customers Served: 77,854 – Sales Per Customer: JPY 7,190 – Customer Repeat Ratio: 77.9% TOKYO, April 25, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company [...]
eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
25/04/2024
Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that [...]
Nexstim Plc: Managers’ Transactions, Niemistö
25/04/2024
Company Announcement, Helsinki, 25 April 2024 at 1 PM (EEST) Nexstim Plc: Managers’ Transactions, Niemistö Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to [...]
Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
25/04/2024
Poster presentation to highlight updated data from ongoing Phase 1/2 of EO2463 monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL) PARIS, April 25, 2024 (GLOBE [...]
Orion Group Interim Report January–March 2024
25/04/2024
ORION CORPORATION INTERIM REPORT 1-3/2024 25 APRIL 2024 at 12:00 EEST Orion Group Interim Report January–March 2024 Net sales totalled EUR 308.5 (January–March 2023: 277.9) million Operating profit was EUR 56.0 (55.5) [...]
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
25/04/2024
Press release PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers Paris (France), April 25, 2024 – PEP-Therapy, a clinical-stage [...]
PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas
25/04/2024
Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas Paris (France), le 25 [...]
Less than half of veterinary professionals feel their profession is appreciated
25/04/2024
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated. Veterinary associations and Boehringer Ingelheim [...]
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024
25/04/2024
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024 UllCORE is designed to transform life-saving clinical decision making for sepsis patients Barcelona, Spain [...]
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
25/04/2024
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, [...]

Pages